GC Wealth Management RIA’s Edwards Lifesciences EW Stock Holding History

GC Wealth Management RIA’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,790	Closed	-$995K	–	627
2025 Q3	$995K	Buy	12,790 +8,900	+229%	+$695K	0.03%	329
2025 Q2	$304K	Buy	+3,890	New	+$290K	0.02%	431

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

GC Wealth Management RIA's EW Position: Q4 2025 in Review

GC Wealth Management RIA sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 12,790 shares — an estimated $995K sold.

GC Wealth Management RIA first reported a position in EW in Q2 2025 and held it in 2 quarters. The position peaked at $995K in Q3 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

GC Wealth Management RIA reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
GC Wealth Management RIA sold 12,790 Edwards Lifesciences shares in Q4 2025, an estimated $995K.
GC Wealth Management RIA first reported a position in Edwards Lifesciences in Q2 2025 and held it in 2 quarters.
GC Wealth Management RIA's Edwards Lifesciences position peaked at $995K in Q3 2025.
1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on GC Wealth Management RIA's 13F filing for Q4 2025, filed 30 Jan 2026.